Adverse Events Module

Adverse Events Module

For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.

Adverse Events Module path is as follows:

Study -> Results Section -> Adverse Events Module -> Event Groups

Study -> Results Section -> Adverse Events Module -> Serious Events

Study -> Results Section -> Adverse Events Module -> Other Events

Adverse Events Module


Ignite Creation Date: 2025-12-25 @ 3:29 AM
Ignite Modification Date: 2025-12-26 @ 2:11 AM
NCT ID: NCT03099005
Description: None
Frequency Threshold: 0
Time Frame: Adverse event data were collected during the 6 hours following each drug administration.
Study: NCT03099005
Study Brief: Effect of Cannabis and Endocannabinoids on HIV Neuropathic Pain
Event Groups(If Any):

Event Groups

Title Description Deaths # Affected Deaths # At Risk Serious # Affected Serious # At Risk Other # Affected Other # At Risk View
Low CBD Session In the morning, participants will inhale 8 puffs of vaporized cannabis containing 1.9% THC + 0.01 CBD. They will then undergo experimental testing as described below under Outcome Measures. Cannabis: vaporization of cannabis 0 None 0 5 3 5 View
Medium CBD Session In the morning, participants will inhale 8 puffs of vaporized cannabis 4 puffs will contain 1.9% THC + 0.01 CBD and 4 puffs will contain 1.4% THC + 5.1% CBD. They will then undergo experimental testing as described below under Outcome Measures. Cannabis: vaporization of cannabis 0 None 0 5 2 5 View
High CBD Session In the morning, participants will inhale 8 puffs of vaporized cannabis containing 1.4% THC + 5.1% CBD. They will then undergo experimental testing as described below under Outcome Measures. Cannabis: vaporization of cannabis 0 None 0 5 2 5 View
Serious Events(If Any):
Other Events(If Any):

Other Events

Term Type Organ System Vocab View
Drowsiness SYSTEMATIC_ASSESSMENT General disorders None View
Dry Mouth SYSTEMATIC_ASSESSMENT General disorders None View
Cognitive Impairment SYSTEMATIC_ASSESSMENT General disorders None View